CompletedNot Applicable

BIO-PREDISC-TIA SWISS Cohort Study

Switzerland64 participantsStarted 2017-08-04

Plain-language summary

This research project aims at contributing to improve TIA diagnosis and management by using PREDISC scores and specific biomarkers thought to have elevated levels in TIA patients. A swift and accurate TIA diagnosis allows starting treatment of the patient adequately and shortly after the event. The shorter the time between the event and treatment onset, the better the outcome. This approach will be an important step forward in TIA diagnosis and management, similarly to acute coronary syndrome as discussed above.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with suspected TIA (defined as the acute onset of focal neurological symptoms lasting \<24 h and presumed to be caused by brain ischemia at the time of referral) within 48 h of symptoms onset. * At least 18 years old. * Having given their Informed Consent. Exclusion Criteria: * · Patients with ocular TIA (Amaurosis fugax). * Patients that still have neurological deficits at the moment of inclusion. * Contraindication to perform MRI. * For women: pregnancy.

What they're measuring

Levels of specific biomarkers (Platelet Basic Protein (PBP), ceruloplasmin, microRNAs, exosomal particles) in patients with suspected TIA.

Timeframe: 1 year

Trial details

NCT IDNCT03994003

SponsorDr. med. Carlo Cereda

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2020-12-31

View on ClinicalTrials.gov More Cerebrovascular Disease, Ischemic Stroke trials